Citas bibligráficas
Villanueva, A., Trabucco, C. (2021). Eficacia y seguridad de los estilbenos en el manejo de la sintomatología climatérica en mujeres de edad mediana: Una revisión sistemática [Tesis, Universidad Peruana de Ciencias Aplicadas (UPC)]. http://hdl.handle.net/10757/655345
Villanueva, A., Trabucco, C. Eficacia y seguridad de los estilbenos en el manejo de la sintomatología climatérica en mujeres de edad mediana: Una revisión sistemática [Tesis]. PE: Universidad Peruana de Ciencias Aplicadas (UPC); 2021. http://hdl.handle.net/10757/655345
@misc{renati/394566,
title = "Eficacia y seguridad de los estilbenos en el manejo de la sintomatología climatérica en mujeres de edad mediana: Una revisión sistemática",
author = "Trabucco Puicón, Claudia Estefany",
publisher = "Universidad Peruana de Ciencias Aplicadas (UPC)",
year = "2021"
}
Objective: To synthesize the evidence regarding the efficacy and safety of stilbenes to treat climacteric symptoms in middle-aged women. Methods: We conducted a systematic literature review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched in Pubmed-Medline, Embase, Scopus, Web of Science, WOS-Medline, LILACS, CINAHL, PsycINFO, SciELO, CENTRAL and international registries of clinical trials, about the efficacy and safety of stilbenes in climacteric symptomatology. We consulted grey literature sources, until December 2018, without language restriction. We used the Cochrane Collaboration tool for risk of bias assessment of the included studies. Results: We obtained 2752 records in the primary search, from which we selected four randomized controlled trials (RCTs) that reported efficacy and safety outcomes. We found that the included clinical trials were highly heterogeneous in terms of dose, combinations with other phytoestrogens, duration of supplementation, measurement scales, and outcome reporting. Regarding efficacy, one trial reported a significant decrease in all somatic symptoms in the resveratrol group, with the most significant reduction in muscular and joint discomfort, where only 16.7% of the population reported these symptoms at the end of the intervention, compared to 73.3% for the placebo arm (p<0.001). On the other hand, a second RCT showed significant improvement in the number (p=0.0077) and intensity (p=0.018) of vasomotor episodes in the intervention group. In contrast, a third trial showed non-significant differences in the somatic subscale total score, (7.7 ± 2.2; p ITT= 0.760) for the intervention group and (8.6 ± 2.2; p ITT= 0.760) for the control group. In terms of safety, two of four RCTs reported the absence of adverse events with resveratrol supplementation. Conclusion: Evidence from included RCTs is inconclusive regarding the efficacy of stilbene supplementation, particularly resveratrol, to manage climacteric symptomatology. Clinical trials reported the absence of adverse events with resveratrol supplementation, although this outcome was assessed in only half of the studies. Thus, future randomized clinical trials with a better design and larger sample are required to reach a definitive conclusion on stilbenes's use.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons